I haven’t seen the anecdotal case hx with the use of baracitnib in COVID-19 patients; but, I believe all the JAK inhibitors have a black box warning for thrombosis. As we know that hypercoagulability is likely the cause of much of the morbidity/mortality w/ COVID-19, this is a surprising choice for an anti-inflammatory to be tested in joint administration with Remdesivir.